The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis
- PMID: 35162776
- PMCID: PMC8835448
- DOI: 10.3390/ijerph19031753
The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis
Abstract
Background: Migraine is a common and disabling primary headache disorder, associated with many medical comorbidities, highly prevalent, with complex treatment and management. Currently, monoclonal antibodies targeting the trigeminal sensory neuropeptide, calcitonin gene-related peptide (CGRP), are available. The aim of this protocol is to provide a review comparing the effects and safety profile of different monoclonal antibodies in migraine patients.
Methods: The literature search will be performed through the MEDLINE, Embase, CENTRAL, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP), Web of Science and Scopus databases, following the PICO strategy. Real World studies and randomized clinical trials assessing the effect of monoclonal antibodies against CGRP interventions (erenumab, eptinezumab, fremanezumab and galcanezumab) on monthly migraine days (MMD), monthly headache days (MHD), headache impact test (HIT-6) and triptan days of use (TriD) will be included. In Real World studies, the DerSimonian and Laird method will be used to calculate pooled estimates of the mean change difference and in randomized clinical trials, a network meta-analysis will be performed to estimate the comparative effects of different monoclonal antibodies against CGRP.
Results: The findings of this study will be reported in a peer-reviewed journal.
Conclusions: This study will provide evidence to health professionals on the efficacy and safety of different monoclonal antibodies against CGRP on the outcomes studied.
Keywords: calcitonin gene-related peptide (CGRP); eptinezumab; erenumab; fremanezumab; galcanezumab; meta-analysis; migraine prevention; monoclonal antibodies; protocol; review.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
CROATIAN GUIDELINES FOR SPECIFIC PREVENTIVE TREATMENT OF MIGRAINE WITH MONOCLONAL ANTIBODIES TARGETING CALCITONIN GENE-RELATED PEPTIDE (CGRP) (EPTINEZUMAB, FREMANEZUMAB, AND GALCANEZUMAB) OR THE CGRP RECEPTOR (ERENUMAB).Acta Clin Croat. 2024 Oct;63(2):436-450. doi: 10.20471/acc.2024.63.02.22. Acta Clin Croat. 2024. PMID: 40104234 Free PMC article. Review.
-
The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.Neurol Sci. 2018 Dec;39(12):2097-2106. doi: 10.1007/s10072-018-3547-3. Epub 2018 Sep 4. Neurol Sci. 2018. PMID: 30182284
-
Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis.BMC Neurol. 2020 Feb 15;20(1):57. doi: 10.1186/s12883-020-01633-3. BMC Neurol. 2020. PMID: 32061264 Free PMC article.
-
A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.Headache. 2023 Jun;63(6):788-794. doi: 10.1111/head.14528. Epub 2023 May 31. Headache. 2023. PMID: 37254581
-
Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.Headache. 2020 Nov;60(10):2454-2462. doi: 10.1111/head.13956. Epub 2020 Sep 23. Headache. 2020. PMID: 32969035
Cited by
-
Efficacy and Safety of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Preventing Migraines: A Systematic Review.Cureus. 2023 Sep 19;15(9):e45560. doi: 10.7759/cureus.45560. eCollection 2023 Sep. Cureus. 2023. PMID: 37868560 Free PMC article. Review.
-
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.Eur J Med Res. 2022 Jun 4;27(1):86. doi: 10.1186/s40001-022-00716-w. Eur J Med Res. 2022. PMID: 35659086 Free PMC article.
-
Comparison of indirect treatment methods in migraine prevention to address differences in mode of administration.J Comp Eff Res. 2023 Jul;12(7):e230021. doi: 10.57264/cer-2023-0021. Epub 2023 May 24. J Comp Eff Res. 2023. PMID: 37222593 Free PMC article. Review.
References
-
- Pescador Ruschel M.A., De Jesus O. Migraine Headache. StatPearls Publishing; Treasure Island, FL, USA: 2021.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials